92 related articles for article (PubMed ID: 19580807)
1. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Cortes-Burgos LA; Zweifel BS; Settle SL; Pufahl RA; Anderson GD; Hardy MM; Weir DE; Hu G; Happa FA; Stewart Z; Muthian S; Graneto MJ; Masferrer JL
Eur J Pharmacol; 2009 Sep; 617(1-3):59-67. PubMed ID: 19580807
[TBL] [Abstract][Full Text] [Related]
2. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
Masferrer JL; Zweifel BS; Hardy M; Anderson GD; Dufield D; Cortes-Burgos L; Pufahl RA; Graneto M
J Pharmacol Exp Ther; 2010 Jul; 334(1):294-301. PubMed ID: 20378715
[TBL] [Abstract][Full Text] [Related]
4. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
Horrillo R; Planagumà A; González-Périz A; Ferré N; Titos E; Miquel R; López-Parra M; Masferrer JL; Arroyo V; Clària J
J Pharmacol Exp Ther; 2007 Dec; 323(3):778-86. PubMed ID: 17766677
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats.
Rzodkiewicz P; Gasinska E; Maslinski S; Bujalska-Zadrozny M
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):213-9. PubMed ID: 25425056
[TBL] [Abstract][Full Text] [Related]
6. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
Matthew Hutzler J; Linder CD; Melton RJ; Vincent J; Daniels JS
Drug Metab Dispos; 2010 Jul; 38(7):1113-21. PubMed ID: 20375180
[TBL] [Abstract][Full Text] [Related]
7. Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells.
Li CT; Zhang WP; Lu YB; Fang SH; Yuan YM; Qi LL; Zhang LH; Huang XJ; Zhang L; Chen Z; Wei EQ
J Neurosci Res; 2009 Mar; 87(4):991-1001. PubMed ID: 18951527
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
Singh VP; Patil CS; Kulkarni SK
Pharmacol Biochem Behav; 2005 Jul; 81(3):433-9. PubMed ID: 15935457
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
10. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Fischer L; Steinhilber D; Werz O
Br J Pharmacol; 2004 Jul; 142(5):861-8. PubMed ID: 15197110
[TBL] [Abstract][Full Text] [Related]
11. 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5,6- tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics.
Mano T; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K; Stevens RW
J Med Chem; 2004 Jan; 47(3):720-5. PubMed ID: 14736252
[TBL] [Abstract][Full Text] [Related]
12. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
[TBL] [Abstract][Full Text] [Related]
14. A novel inhibitor of active protein kinase G attenuates chronic inflammatory and osteoarthritic pain.
Sung YJ; Sofoluke N; Nkamany M; Deng S; Xie Y; Greenwood J; Farid R; Landry DW; Ambron RT
Pain; 2017 May; 158(5):822-832. PubMed ID: 28059868
[TBL] [Abstract][Full Text] [Related]
15. 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Tu XK; Yang WZ; Shi SS; Chen CM; Wang CH
Neurol Res; 2009 Oct; 31(8):848-52. PubMed ID: 19309543
[TBL] [Abstract][Full Text] [Related]
16. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Patel NS; Cuzzocrea S; Chatterjee PK; Di Paola R; Sautebin L; Britti D; Thiemermann C
Mol Pharmacol; 2004 Aug; 66(2):220-7. PubMed ID: 15266012
[TBL] [Abstract][Full Text] [Related]
17. [Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats].
Chen W; Li C; Zhao J; Zhang X; Han H; Wei E; Zhang L
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Jan; 42(1):61-6. PubMed ID: 23505109
[TBL] [Abstract][Full Text] [Related]
18. Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain.
Singh VP; Patil CS; Kulkarni SK
Pharmacol Rep; 2005; 57(3):380-4. PubMed ID: 15985722
[TBL] [Abstract][Full Text] [Related]
19. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
